Ad­di­tion­al drug­mak­ers flag risks of work­ing with WuXi amid height­ened US scruti­ny

More drug com­pa­nies are dis­clos­ing the po­ten­tial for clin­i­cal tri­al de­lays and drug short­ages if the US gov­ern­ment black­lists a fam­i­ly of WuXi com­pa­nies used across the bio­phar­ma in­dus­try.

The dis­clo­sures come from com­pa­nies large and small, in­clud­ing Mer­ck, Ca­balet­ta Bio and Kyver­na Ther­a­peu­tics. Through se­cu­ri­ties fil­ings, End­points News iden­ti­fied near­ly three dozen com­pa­nies that re­ly on WuXi and have flagged the risk of a crack­down. The tal­ly is more than dou­ble since March 13, when End­points first com­piled a list of po­ten­tial­ly af­fect­ed com­pa­nies.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER